Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/gileads-recently-acquired-liver-disease-med-continues-deliver-goods-ahead-fda-verdict
https://www.globenewswire.com//news-release/2024/03/04/2839523/37067/en/CymaBay-Announces-European-Medicines-Agency-Accepts-for-Review-the-Marketing-Authorization-Application-for-Seladelpar-for-the-Treatment-of-Primary-Biliary-Cholangitis.html
https://www.globenewswire.com//news-release/2024/02/28/2837495/37067/en/CymaBay-Reports-Fourth-Quarter-and-Year-Ended-December-31-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.fiercebiotech.com/biotech/cymabay-board-pushed-50-cent-top-gileads-3250-share-offer
https://www.prnewswire.com/news-releases/the-new-england-journal-of-medicine-publishes-positive-phase-3-response-data-of-cymabays-seladelpar-in-primary-biliary-cholangitis-302068089.html
https://www.globenewswire.com//news-release/2024/02/20/2832269/37067/en/CymaBay-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.gilead.com/news-and-press/press-room/press-releases/2024/2/gilead-sciences-expands-liver-portfolio-with-acquisition-of-cymabay-therapeutics
https://www.prnewswire.com/news-releases/cymabay-announces-fda-acceptance-of-nda-and-priority-review-for-seladelpar-for-the-treatment-of-primary-biliary-cholangitis-302059522.html